Reason #2: The Partnership Reminder Was Key
Aside from the share repurchase program showing that management’s interests are aligning with those of investors, the partnership reminder was also very important. Keep in mind that CanSinoBIO will be responsible for all CMC development activities as well as manufacturing clinical supplies.
This is a crucial factor. Ultimately, it means that the partnership takes a great amount of operational and financial strain off of the company’s back when it comes to the development of OCU400.
As a result of this partnership, the company can continue the development of OCU400 while maintaining a strong financial foundation that will provide it a runway which should get it through plenty of catalysts.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Click below to continue reading!